Sun Pharmaceutical Industries Gets CDSCO Panel Nod to Study FDC of Relugolix, Estradiol, Norethindrone Acetate

This came after the drug major Sun Pharmaceutical Industries presented the proposal before the committee for CT waiver and the published safety and efficacy data.

The committee did not agree to the clinical trial waiver and the firm was asked to present Phase III CT protocol in continuation with an earlier SEC recommendation dated 19th December 2023.

In continuation with the above, the committee recommended for conducting the Phase III clinical trial as per the protocol presented by the firm.

Relugolix is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication that is used in the treatment of prostate cancer in men and uterine fibroids in women.

Estradiol is used for hormone replacement therapy and post-menopausal osteoporosis. Estradiol is an estrogen (female sex hormone). In women who are undergoing or have attained menopause, it prevents symptoms such as hot flashes, night sweats, and mood swings. It also prevents the bones from becoming porous and fragile (osteoporosis).

Norethisterone is a synthetic second-generation progestin used for contraception, prevention of endometrial hyperplasia in hormone replacement therapy, and in the treatment of other hormone-mediated illnesses such as endometriosis.

At the recent SEC meeting for the Reproductive held on 20th March 2024, the expert panel reviewed the proposal presented by the drug major Sun Pharmaceutical Industries regarding the FDC Relugolix, Estradiol, and Norethindrone Acetate Tablets.

After detailed deliberation, the committee recommended the conducting of a Phase III clinical trial as per the protocol presented by the firm.